Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis PharmaceuticalsMEX:IONS 73 Equity-to-Asset is 0.15 as of Jun. 2026, which is 32% below its 10-year median of 0.22. GuruFocus rates MEX:IONS with a GF Score™ of 73/100 and a GF Value™ of MXN992.71. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Ionis Pharmaceuticals ranks worse than 83.53% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ionis Pharmaceuticals Equity-to-Asset Related Terms
Ionis Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IONS vs KYMR, PRAX, HALO: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ionis Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (MEX:IONS) has a Equity-to-Asset of 0.15 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ionis Pharmaceuticals and its competitors. This is 32% below median its historical median of 0.22. Over the past decade, Ionis Pharmaceuticals' Equity-to-Asset has ranged from 0.10 to 0.46. According to the industry distribution chart, Ionis Pharmaceuticals ranks #1182 out of 1415 companies in the Biotechnology industry, placing it in the top 83.5%.
Is Ionis Pharmaceuticals' Equity-to-Asset too high?
Ionis Pharmaceuticals' current Equity-to-Asset of 0.15 is 32% below median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.46. The Biotechnology industry median Equity-to-Asset is 0.68. Ionis Pharmaceuticals' value of 0.15 is 77.9% below this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #1182 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ionis Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Equity-to-Asset compare to KYMR and PRAX?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #1182 out of 1415 companies for Equity-to-Asset. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Ionis Pharmaceuticals' value of 0.15 is 77.9% below this benchmark. Historically, Ionis Pharmaceuticals' own Equity-to-Asset has ranged from 0.10 to 0.46 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.68, Ionis Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Equity-to-Asset of 0.15 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Equity-to-Asset is 0.15, which is 32% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Equity-to-Asset of 0.15. The stock's GF Value™ is MXN992.71, compared to a current price of MXN1,150.00 — trading 15.8% above its estimated fair value. The current Equity-to-Asset is 0.15, which is 32% below median its 10-year median of 0.22 and 77.9% below the Biotechnology industry median of 0.68. Ionis Pharmaceuticals' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Equity-to-Asset is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 15.8% above its estimated GF Value™ of MXN992.71.
Key valuation signals for MEX:IONS:
Equity-to-Asset: 0.15 (32% below median its 10-year median of 0.22)
GF Value™: MXN992.71 vs. price of MXN1,150.00 (15.8% above fair value)
Industry Position: 77.9% below the Biotechnology median (#1182 of 1415)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
73GF Score
Get the complete analysis for MEX:IONS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
